March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE (SBLA) APPLICATION FOR ILUMYA® (TILDRAKIZUMAB-ASMN) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
SUN PHARMA - FDA REGULATORY ACTION DATE FOR ILUMYA SBLA EXPECTED BY OCTOBER 29, 2026